| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Infliximab and Anti-Infliximab Antibody, DoseASSURE IFX
Test CodeLAB00109
Alias/See Also
LAB00109
LabCorp TC: 503870
Anti-TNF-alpha Drug
IFD
Remicade
LabCorp TC: 503870
Anti-TNF-alpha Drug
IFD
Remicade
CPT Codes
80230, 82397
Includes
Infliximab Drug Level Infliximab (IFX) Conc+IFX Ab
Anti-Infliximab Antibody
Anti-Infliximab Antibody
Preferred Specimen
2 mL Serum
(Marble, Gold, Red)
(Marble, Gold, Red)
Minimum Volume
1 mL
Instructions
Serum must be separated from cells within 45 minutes of venipuncture. Send serum in a plastic transport tube. To avoid delays in turnaround time when requesting multiple test on frozen samples, please submit separate frozen specimens for each test requested.
Transport Temperature
FROZEN
Specimen Stability
Frozen: 359 days
Methodology
Electrochemiluminescence Immunoassay (ECLIA)
Report Available
5-10 days
Limitations
Failure of infliximab therapy may not always be due to the presence of anti-infliximab antibodies. In addition, the absence of anti-infliximab antibodies does not guarante positive response to treatment.
Clinical Significance
Provides infliximab drug concentration levels as well as levels of anti-infliximab antibodies.
In the absence of anti-infliximab antibodies, the infliximabdrug level typically reflects the total infliximab concentration in serum. In the presence of anti-infliximab antibodies, the infliximab drug level typically reflects theantibody-unbound fraction of infliximab concentration in serum. The presence of infliximab drug, even at concentrations well above target treatment levels (>50 ug/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rhematoid arthritis, or other autoimmune conditions. This test includes long-term serial monitoring of results.
In the absence of anti-infliximab antibodies, the infliximabdrug level typically reflects the total infliximab concentration in serum. In the presence of anti-infliximab antibodies, the infliximab drug level typically reflects theantibody-unbound fraction of infliximab concentration in serum. The presence of infliximab drug, even at concentrations well above target treatment levels (>50 ug/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rhematoid arthritis, or other autoimmune conditions. This test includes long-term serial monitoring of results.
Performing Laboratory
LabCorp